688606 奥泰生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.8767.8454.51831.853--
总资产报酬率 ROA (%)4.5047.2874.09927.230--
投入资产回报率 ROIC (%)4.7837.6824.36329.997--

边际利润分析
销售毛利率 (%)56.21255.71848.78259.93355.166
营业利润率 (%)34.56339.87128.03541.13347.867
息税前利润/营业总收入 (%)32.51935.80618.40538.67546.857
净利润/营业总收入 (%)29.96834.95523.88834.98440.871

收益指标分析
经营活动净收益/利润总额(%)80.38684.73882.361118.59096.404
价值变动净收益/利润总额(%)12.73413.73120.9200.6443.158
营业外收支净额/利润总额(%)-0.2580.631-7.163-0.896-0.136

偿债能力分析
流动比率 (X)8.8849.91111.5318.202--
速动比率 (X)8.3369.37510.8437.823--
资产负债率 (%)8.0317.2296.91211.165--
带息债务/全部投入资本 (%)1.6781.7752.0494.131--
股东权益/带息债务 (%)5,844.1505,527.3914,768.3722,313.053--
股东权益/负债合计 (%)1,145.2941,283.4251,345.256794.785--
利息保障倍数 (X)-16.638-8.290-2.373-18.477-49.600

营运能力分析
应收账款周转天数 (天)61.93246.77657.13018.4250.000
存货周转天数 (天)166.081163.664178.00476.5630.000